Department of Obstetrics & Gynecology, "Veris delli Ponti Hospital", Scorrano (Le), Italy.
CERICSAL (CEntro di RIcerca Clinico SALentino, "Veris delli Ponti Hospital", Scorrano (Le), Italy.
Int J Gynaecol Obstet. 2022 Jan;156(1):133-138. doi: 10.1002/ijgo.13692. Epub 2021 May 5.
On May 13, 2020, the Italian government Pharmaceutical Agency (AIFA) stopped ulipristal acetate (UPA) treatments for uterine fibroids (UFs), so patients shifted to other natural treatments. The authors tested the patients' compliance with UF natural treatments.
Thirty patients of reproductive age (30-45 years) affected by UFs stopped UPA intake and started epigallocatechin gallate (EGCG) plus vitamin D3 treatment. Patients were asked to complete the Uterine Fibroid symptoms and Quality of Life (UFS-QOL) questionnaire, divided into symptoms severity (SS) and health-related quality of life (HRQL), after UPA suspension and to repeat it after 3 months of natural treatment. Collected data were analyzed using paired Student's t test, considering a P value less than 0.05 to be significant.
The SS score was significantly lower (-12.19%) for natural treatment when compared with UPA administration. The HRQL score significantly improved (+11.79%) after shifting treatment from UPA to natural therapy. All the investigated parameters appeared improved by 10% after the natural treatment. No adverse effects were reported following the natural treatment.
Natural treatments showed positive compliance in patients with UFs, based on HRQL score, representing an alternative therapeutic opportunity for patients forced to stop UPA therapy.
2020 年 5 月 13 日，意大利政府药品管理局（AIFA）停止了用于治疗子宫肌瘤（UFs）的屈螺酮（UPA）治疗，因此患者转而接受其他自然疗法。作者测试了患者对 UF 自然疗法的依从性。
30 名处于生育年龄（30-45 岁）的 UF 患者停止服用 UPA，并开始接受表没食子儿茶素没食子酸酯（EGCG）加维生素 D3 治疗。要求患者在停止 UPA 治疗后和接受自然治疗 3 个月后填写子宫肌瘤症状和生活质量（UFS-QOL）问卷，分为症状严重程度（SS）和健康相关生活质量（HRQL）两部分。采用配对学生 t 检验分析收集的数据，认为 P 值小于 0.05 具有统计学意义。
与 UPA 给药相比，自然治疗的 SS 评分显著降低（-12.19%）。从 UPA 转为自然疗法后，HRQL 评分显著提高（+11.79%）。所有调查参数在自然治疗后均提高了 10%。自然治疗后未报告不良反应。
基于 HRQL 评分，自然疗法在 UF 患者中表现出良好的依从性，为被迫停止 UPA 治疗的患者提供了另一种治疗机会。
